LANOXin Tablet contains Digoxin 0.25 mg, a cardiac glycoside used primarily in the management of various heart conditions. It exerts its therapeutic effect by inhibiting the sodium-potassium ATPase pump, leading to an increase in intracellular calcium concentration in cardiac myocytes, which enhances myocardial contractility (positive inotropic effect). LANOXin is indicated for the treatment of heart failure, atrial fibrillation, and atrial flutter, helping to improve symptoms and reduce hospitalizations associated with these conditions. It is particularly beneficial in patients with systolic heart failure and those requiring ventricular rate control in supraventricular tachyarrhythmias. The drug has a narrow therapeutic index; therefore, careful dosing and monitoring of serum digoxin levels are essential to avoid toxicity, which may manifest as gastrointestinal disturbances, visual changes, and cardiac arrhythmias. Dose adjustments may be necessary in renal impairment due to digoxin’s renal excretion. Concomitant use with certain medications such as diuretics, amiodarone, or verapamil requires caution due to potential drug interactions. LANOXin should be administered under strict medical supervision with regular assessment of renal function, electrolytes, and clinical response to optimize therapeutic outcomes and minimize adverse effects.